Currently, based on evidence from neuroimaging, postmortem studies, and cerebrospinal fluid testing, BBB dysfunction has been recognized as an early biomarker of neurodegenerative diseases (Yuan, et al
Contact us through our online form to schedule your consultation.
The new membersdrawn from clinical research, neurology, gastroenterology, pain management, and patient advocacywere described by former FDA official Peter Lurie as "considerably more qualified and less conflicted." Several were limited to specific peptides, including one expert restricted to BPC-157
He is on the editorial boards of numerous scientific and medical journals and has been a consultant to many re-search organizations in industry and government
Most practitioners report subjective improvement after 8 to 12 weeks of consistent dosing